思特奇(300608.SZ)半年度淨虧損收窄至759.66萬元
格隆匯8月14日丨思特奇(300608.SZ)發佈2019年半年度報告,實現營業收入2.93億元,同比增長21.58%;歸屬於上市公司股東的淨虧損759.66萬元,同比減少41.46%;基本每股虧損0.07元。
2019年上半年,公司秉承“在人工智能、雲、大數據、萬物互聯和智慧運營時代,成為產品、技術、服務、運營的可信賴專家”的宗旨,堅持“為客户創造價值,成為客户長期、最佳、可信賴合作伙伴”的戰略目標,依託深厚的資源積累及前瞻性的產品佈局,以市場需求為導向,圍繞雲計算、大數據、移動互聯網、物聯網等方向,不斷拓展和創新,積極貫徹落實企業發展戰略與年度經營計劃,總體上保持了良好的發展態勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.